Predict immunotherapy response using live tumor tissue
Today, there is no reliable way to determine which immunotherapy a cancer patient will respond to. Current “omics” solutions fall short for predicting response to immunotherapy. The biological complexity of a live sample is too intricate for traditional approaches to measure.
Because of this, only 1 in 5 patients respond to immunotherapy today
At ElephasTM Biosciences, we aim to close the gap in the ability to predict immunotherapy response with an innovative platform
We have developed a platform that utilizes fresh tumor biopsies to preserve the tumor microenvironment for evaluating immunotherapy response. Standard of care biopsies are prepared using proprietary instruments to cut and encapsulate them, keeping tissue alive throughout assessment on the Elephas Live™ platform.
The live biopsy is then assessed for viability, tumor content, and response to immunotherapy over time. Advanced imaging technology has the capability to nondestructively capture data at multiple time points to predict response to immunotherapy before treatment begins, and within 72 hours of biopsy.
The curation of an unprecedented, proprietary dataset provides a unique opportunity for investigation into mechanisms of immunotherapy response. Secure, centralized data aggregation and analysis empower providers with essential information to determine appropriate therapy. Data can be accessed from anywhere via the cloud-based portal that provides the highest level of data security for customers by safeguarding information through industry-leading best practices. Learn more in our Trust Center.
Platform is designed for placement in pathology labs, enabling providers to predict the efficacy of any standard of care therapy using only a core needle biopsy.
